Skip to main content
. 2023 May 9;4(3):e257. doi: 10.1002/mco2.257

FIGURE 7.

FIGURE 7

Far upstream element‐binding protein 1 (FUBP1) confers chemoresistance to osteosarcoma cells through the arachidonic acid metabolic pathway. (A) Western blotting analysis of prostaglandin E synthase (PTGES) in osteosarcoma cells transfected with FUBP1‐overexpressing plasmids or siFUBP1. (B) The effect of PTGES overexpression on the sensitivity of FUBP1 knockdown osteosarcoma cells treated with lobaplatin for 24 h detected using flow cytometry. (C) The effect of PTGES overexpression on the sensitivity of FUBP1 knockdown osteosarcoma cells treated with lobaplatin evaluated with a colony formation assay. (D) The effect of PTGES overexpression on the sensitivity of FUBP1 knockdown osteosarcoma cells treated with lobaplatin evaluated by western blotting using a cleaved poly (ADP‐ribose) polymerase (PARP) antibody. (E) The effect of PTGES overexpression on prostaglandin E2 (PGE2) and leukotriene B4 (LTB4) secretion in FUBP1 knockdown osteosarcoma cells evaluated by ELISA. (F) The effect of a selective PTGES inhibitor CAY10526 on the sensitivity of FUBP1‐overexpressing osteosarcoma cells treated with lobaplatin evaluated by CCK‐8 assays. (G) The effect of an EP2 receptor agonist Evatanepag on the sensitivity of FUBP1 knockdown osteosarcoma cells treated with lobaplatin evaluated by CCK‐8 assays. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.